Catalyst Pharmaceuticals (CPRX)
(Real Time Quote from BATS)
$13.80 USD
-0.35 (-2.47%)
Updated Dec 11, 2023 02:50 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Price, Consensus and EPS Surprise
CPRX 13.80 -0.35(-2.47%)
Will CPRX be a Portfolio Killer in December?
Zacks Investment Research is releasing its prediction for CPRX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CPRX
Why Is Catalyst (CPRX) Up 16.2% Since Last Earnings Report?
Catalyst (CPRX) Q3 Earnings Miss, Sales Top, '23 View Up
CPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?
Amylyx Pharmaceuticals, Inc. (AMLX) Earnings Expected to Grow: What to Know Ahead of Q3 Release
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Other News for CPRX
Insider Sell Alert: Chief Med. & Reg. ...
Catalyst Pharmaceuticals Inc. stock underperforms Friday when compared to competitors
Catalyst Pharmaceuticals Inc. stock outperforms market on strong trading day
Catalyst Pharmaceuticals Inc. stock falls Wednesday, underperforms market
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies